E2F4 Antibody

What is E2F4 and why is it important in scientific research?

• Cell cycle regulation and proliferation

• Transcriptional control of key metabolic and biosynthetic genes

• Stem cell expansion and maintenance of pluripotency

• Cancer progression and potential prognostic value

E2F4 has been found to directly activate the transcription of cell cycle genes in mouse embryonic stem cells (mESCs) and promote their expansion . Additionally, E2F4 is upregulated in several cancer types, including head and neck squamous cell carcinoma (HNSCC), where its high expression correlates with poor prognosis .

What are the common techniques for detecting E2F4 expression in tissue samples?

Several validated techniques are commonly employed for E2F4 detection:

• Immunohistochemistry (IHC): Using rat anti-human E2F4 monoclonal antibodies for tissue sections. This technique has successfully demonstrated that E2F4 is primarily localized in the cell nucleus in HNSCC tissues .

• Western Blotting: For protein expression analysis in cell lysates.

• Chromatin Immunoprecipitation (ChIP): To identify E2F4 binding sites across the genome.

• RNA analysis methods: RT-qPCR to analyze expression of E2F4 and its target genes.

For IHC specifically, a standardized scoring system can be implemented based on:

• Staining intensity (0-3 scale: negative, yellowish, brown, dark brown)

• Percentage of positive cells (0-3 scale: <10%, 10-25%, 26-70%, >70%)

• Final score calculated by multiplying these parameters (range: 0-9)

How do I select the appropriate E2F4 antibody for my specific research application?

Selection criteria for E2F4 antibodies should consider:

• Experimental application: Different applications (IHC, Western blot, ChIP) may require antibodies with different properties. For example, for immunohistochemistry of paraffin-embedded tissues, use antibodies validated for this application as demonstrated in the HNSCC study .

• Species reactivity: Ensure the antibody recognizes E2F4 in your study species. The literature shows successful use of rat anti-human E2F4 monoclonal antibodies for human samples .

• Epitope location: Consider whether you need antibodies targeting specific domains of E2F4, particularly if studying truncation variants like the T360 variant .

• Validation data: Review published literature for antibodies used in similar applications. The antibodies used in the HNSCC studies were validated with appropriate positive and negative controls .

How can E2F4 antibodies be used to investigate the dual activator/repressor functions of E2F4?

Recent research has revealed that E2F4 functions as both an activator and repressor in certain contexts, particularly in mouse embryonic stem cells:

• ChIP-seq combined with RNA-seq: This approach revealed that E2F4 directly binds to and activates cell cycle genes in mESCs. E2F4 binding was significantly enriched at the promoters of genes downregulated in E2F4KO cells (p = 0.0069), suggesting direct activation .

• Co-immunoprecipitation with mass spectrometry: This technique identified 108 potential E2F4 interaction partners in TKO (Rb family knockout) mESCs, with 95 of these partners being specific to mESCs and not found in differentiated cells .

• ChIP followed by histone modification analysis: This approach demonstrated that E2F4 recruits histone acetyltransferase complexes to mediate transcriptional activation of target genes .

For studying this dual functionality, researchers should design experiments that combine E2F4 antibody-based chromatin immunoprecipitation with analysis of activating histone marks (H3K27ac) versus repressive marks to distinguish between genes activated versus repressed by E2F4.

What methodological considerations are important when using E2F4 antibodies for ChIP-seq experiments?

When conducting ChIP-seq experiments with E2F4 antibodies:

• Antibody validation: Confirm specificity using E2F4 knockout cells as negative controls, as demonstrated in the mESC studies .

• Fixation conditions: Optimize formaldehyde concentration and fixation time for E2F4, which as a transcription factor may require different conditions than histone proteins.

• Sonication parameters: Adjust to generate appropriate fragment sizes (typically 200-500bp).

• Appropriate controls: Include:

  • Input DNA controls

  • IgG controls

  • Ideally, E2F4 knockout cells as negative controls

• Cross-validation: Confirm key findings with secondary methods such as ChIP-qPCR for selected targets like canonical E2F targets (Dhfr, Mcm3, Pcna, Ccne2) .

The integration of ChIP-seq with RNA-seq data from matched samples can provide powerful insights into direct versus indirect regulation by E2F4, as demonstrated in the mESC studies where direct E2F4 targets were found enriched in the downregulated gene set .

How can E2F4 antibodies be used to investigate the relationship between E2F4 and immune cell infiltration in tumors?

E2F4 expression has been associated with immune infiltration in HNSCC. Methodological approaches include:

• Multiplex immunohistochemistry: Use E2F4 antibodies alongside markers for immune cell subsets (CD4+ T cells, CD8+ T cells, Tregs, macrophages).

• Computational analysis of expression data: Correlate E2F4 expression with immune cell signatures using tools like CIBERSORT and TIMER2.0 .

Research has shown E2F4 expression is negatively correlated with infiltration by several T cell subsets including:

• CD4+ T cells (R = -0.185, P = 1.47e-04)

• CD8+ T cells (R = -0.185, P = 3.47e-05)

• Treg cells (R = -0.232, P = 2.03e-07)

• T cell follicular helper cells (R = -0.208, P = 3.34e-06)

Interestingly, E2F4 expression positively correlates with immune purity (R = 0.123, P = 6.35e-03) and M2 macrophages (R = 0.121, P = 7.41e-03) .

These findings suggest E2F4 may influence tumor immune microenvironment, potentially through regulation of chemokine expression or other immune modulatory factors.

What are common challenges in E2F4 immunohistochemistry and how can they be addressed?

Common challenges and solutions include:

• Antigen retrieval optimization: E2F4 detection in FFPE tissues requires effective antigen retrieval. The HNSCC studies utilized high-pressure antigen retrieval for optimal results .

• Non-specific staining:

  • Use appropriate blocking reagents

  • Include validated positive controls (confirmed positive HNSCC tissues)

  • Include negative controls (PBS instead of primary antibody)

• Signal intensity variations:

  • Standardize fixation protocols

  • Optimize antibody concentration

  • Use quantitative scoring systems as implemented in the HNSCC studies

• Nuclear vs. cytoplasmic staining: While E2F4 is predominantly nuclear in HNSCC cells , cytoplasmic expression has also been observed in mESCs . When evaluating E2F4 staining, consider potential biological significance of different subcellular localizations.

How can I validate the specificity of E2F4 antibodies in my experimental system?

Comprehensive validation approaches include:

• Gene knockout controls: Use CRISPR/Cas9-mediated E2F4 knockout cells as negative controls, as implemented in the mESC studies:

  • E2F4 knockout was achieved using specific sgRNAs targeting exons

  • Controls were cells transfected with Cas9 and sgRNAs that retained E2F4 protein

• Rescue experiments: Reintroduce E2F4 expression in knockout cells to verify antibody specificity and phenotypic effects:

  • Vectors expressing GFP-E2F4, GFP-DBDm (DNA-binding domain mutant), and GFP-T360 (truncation variant) have been validated for rescue experiments

• Peptide competition assays: Pre-incubate antibody with purified E2F4 protein or peptide before staining.

• Cross-validation: Use multiple antibodies targeting different E2F4 epitopes to confirm staining patterns.

• Western blot correlation: Confirm antibody recognizes a protein of the expected molecular weight in your experimental system.

How is E2F4 expression analyzed in cancer research, and what are the implications for prognosis?

E2F4 expression analysis in cancer involves:

• Database analysis approaches:

  • Mining Gene Expression Omnibus (GEO) datasets

  • Analyzing The Cancer Genome Atlas (TCGA) data

  • Validating with independent clinical cohorts

• Tissue-based analysis:

  • Immunohistochemical evaluation using standardized scoring systems

  • Correlation with clinicopathological characteristics

Research has demonstrated that E2F4 is upregulated in HNSCC tissues compared to normal mucosa, and its expression levels correlate with clinical features:

• Higher expression in advanced T stages (p < 0.05)

• Association with tumor grade

• Correlation with metastatic status (M staging)

Kaplan-Meier curve and Cox analyses indicated that high E2F4 expression correlates with poor prognosis in HNSCC, suggesting its potential use as a prognostic biomarker .

How can E2F4 antibodies be used to investigate E2F4's role in stem cell biology?

E2F4 plays important roles in stem cell biology that can be investigated using antibodies:

• Colony formation assays: E2F4 knockout mESCs formed significantly smaller alkaline phosphatase-positive (AP+) colonies compared to wild-type cells when plated at low density, indicating E2F4's role in stem cell expansion .

• Cell cycle analysis: Flow cytometry combined with E2F4 antibodies can assess how E2F4 affects cell cycle distribution in stem cells.

• ChIP-seq analysis: This revealed that E2F4 directly binds to and activates cell cycle genes and other targets in mESCs .

• Co-immunoprecipitation studies: Identified novel, RB family-independent protein complexes that E2F4 participates in within stem cells .

E2F4 knockout in mESCs resulted in:

• Slower growth in prolonged culture

• Smaller AP+ colonies when plated at low density

• Decreased expression of canonical E2F targets (Dhfr, Mcm3, Pcna, Ccne2)

These findings indicate E2F4 plays a key role in promoting the proliferation and expansion of stem cell populations through direct transcriptional activation of cell cycle genes.

What are the emerging roles of E2F4 in signaling pathways, and how can antibodies help investigate these functions?

E2F4 participates in various signaling pathways that can be investigated using antibody-based approaches:

• Pathway analysis through ChIP-seq and RNA-seq integration:
  KEGG and GO enrichment analyses have revealed E2F4 involvement in multiple signaling pathways including:

  • Cell cycle regulation

  • Spliceosome function

  • WNT signaling pathway

  • cAMP signaling

  • ERBB2, VEGF, and MYC pathways

• Protein complex analysis through co-immunoprecipitation:

  • Mass spectrometry following E2F4 pulldown identified 108 candidate interactors in TKO mESCs

  • 95 of these were specific to mESCs and not found in differentiated cells

  • Many of these factors had not been previously reported to associate with E2F proteins

• Histone modification analysis:

  • E2F4 was found to recruit components of histone acetyltransferase complexes

  • Loss of E2F4 resulted in a global decrease of acetylation, particularly at direct E2F4 targets

These findings suggest E2F4 functions through multiple mechanisms beyond traditional views of E2F4 as primarily a repressive transcription factor in complex with RB family proteins.

What controls should be included when using E2F4 antibodies for different experimental applications?

Proper controls are essential for reliable E2F4 antibody-based experiments:

• For immunohistochemistry:

  • Positive controls: Confirmed positive HNSCC tissues

  • Negative controls: PBS instead of primary antibody

  • Comparative normal tissue: Adjacent non-cancerous mucosa

• For Western blotting:

  • Positive controls: Cell lines with confirmed E2F4 expression

  • Negative controls: E2F4 knockout cells generated by CRISPR/Cas9

  • Loading controls: Housekeeping proteins (β-actin, GAPDH)

• For ChIP experiments:

  • Input DNA (pre-immunoprecipitation)

  • IgG control (same species as E2F4 antibody)

  • Positive control regions (known E2F4 targets)

  • Negative control regions (regions not bound by E2F4)

• For rescue experiments:

  • E2F4KO cells + empty vector

  • E2F4KO cells + wild-type E2F4

  • E2F4KO cells + mutant E2F4 (e.g., DNA-binding domain mutant)

How can researchers optimize E2F4 antibody-based assays for different cell types and tissue samples?

Optimization strategies vary by cell type and assay:

• For stem cells (e.g., mESCs):

  • Consider both nuclear and cytoplasmic E2F4 localization

  • Optimize fixation conditions for better preservation of nuclear architecture

  • Use appropriate culture conditions (e.g., 2i media for naïve state mESCs)

• For cancer tissues (e.g., HNSCC):

  • High-pressure antigen retrieval is effective for FFPE samples

  • Standardized scoring systems improve reproducibility

  • Consider tumor heterogeneity in analysis

• For fresh versus fixed samples:

  • Fresh/frozen samples: Milder fixation conditions (e.g., 1% formaldehyde for 10 min)

  • FFPE samples: Robust antigen retrieval essential

• Cross-species considerations:

  • Verify antibody cross-reactivity for your species of interest

  • Consider epitope conservation when working with animal models

How can E2F4 antibodies be utilized to explore the relationship between E2F4 and cancer immunotherapy responsiveness?

Given E2F4's correlation with immune cell infiltration in HNSCC , several promising research approaches include:

• Multiplex immunohistochemistry:

  • Combining E2F4 antibodies with immune checkpoint markers (PD-1, PD-L1, CTLA-4)

  • Correlating E2F4 expression with immunotherapy response markers

• Patient stratification studies:

  • Analyzing E2F4 expression levels in responders versus non-responders to immunotherapy

  • Building predictive models incorporating E2F4 expression levels

• Mechanistic investigations:

  • ChIP-seq to identify E2F4 regulation of immune-related genes

  • Analysis of E2F4's effects on tumor microenvironment

The negative correlation between E2F4 expression and T cell infiltration (CD4+, CD8+, Treg cells) suggests E2F4 might influence immunotherapy responsiveness through modulation of the tumor immune microenvironment.

What are potential applications of E2F4 antibodies in studying post-translational modifications of E2F4?

E2F4 undergoes various post-translational modifications that affect its function:

• Phosphorylation analysis:

  • Use phospho-specific E2F4 antibodies

  • Combine with mass spectrometry to identify novel modification sites

• Subcellular localization studies:

  • Investigate how modifications affect nuclear versus cytoplasmic localization

  • Compare E2F4 modifications between stem cells and differentiated cells

Research has identified different post-translational modifications on E2F4 between mESCs and differentiated cells, though their biological significance remains to be fully elucidated .

• Functional studies:

  • Generate modification-specific mutants

  • Use antibodies to track how modifications affect:

    • Protein-protein interactions

    • DNA binding capacity

    • Transcriptional activity

How might E2F4 antibodies contribute to understanding E2F4's role in drug resistance mechanisms?

E2F4's involvement in cell cycle regulation and cancer progression suggests potential roles in drug resistance:

• Expression analysis in resistant versus sensitive cells:

  • Compare E2F4 levels and subcellular localization

  • Correlate with resistance phenotypes

• ChIP-seq in drug-resistant models:

  • Identify altered E2F4 binding patterns in resistant cells

  • Correlate with expression of drug resistance genes

• Combination therapy investigations:

  • Test if targeting E2F4-regulated pathways sensitizes resistant cells

  • Use E2F4 antibodies to monitor pathway modulation

• Biomarker development:

  • Evaluate E2F4 as a predictive biomarker for drug response

  • Develop standardized IHC protocols for clinical application